Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

EyePoint, Inc. - Common Stock (NQ:EYPT)

4.990 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about EyePoint, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)
From Levi & Korsinsky, LLP
Via Business Wire
EyePoint (NASDAQ:EYPT) Rallies Despite Wider Q2 Loss as Phase 3 Data Nears ↗
Via Chartmill
EyePoint Inc. (NASDAQ:EYPT) Revenue Beats Estimates, Earnings Miss in Q1 2026 Report ↗
Via Chartmill
Topics Earnings
EyePoint Inc (NASDAQ:EYPT) Stock Falls on Q4 Earnings and Revenue Miss ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
EyePoint’s DURAVYU Misses Primary Endpoint in Phase III Wet AMD Trial ↗
Eyepoint Pharmaceuticals (NASDAQ:EYPT) reported topline results from LUGANO, the first of two Phase III trials evaluating DURAVYU, a vorolanib intravitreal insert, in patients with wet age-related... 
Via MarketBeat
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
These stocks are better bets to skyrocket than the much-hyped rocket stock. 
Via The Motley Fool
News headline image
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears ↗
Eyepoint Pharmaceuticals (NASDAQ:EYPT) executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as... 
Via MarketBeat
News headline image
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions. 
Via The Motley Fool
News headline image
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
EyePoint (EYPT) Q1 2026 Earnings Transcript ↗
EyePoint (EYPT) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗
Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment ↗
EyePoint develops sustained-release treatments for retinal diseases, leveraging proprietary technology and strategic industry partnerships. 
Via The Motley Fool
News headline image
EyePoint (EYPT) Q4 2025 Earnings Call Transcript ↗
EyePoint (EYPT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in... 
Via MarketMinute
News headline image
The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year... 
Via MarketMinute
Topics Artificial Intelligence ETFs Initial Public Offering
News headline image
Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles
In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index (RUT) surged to a new record high on January 8, 2026, signaling a definitive breakout for small-cap stocks. As... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens
As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Small-Cap Renaissance: Why 2026 is the Year of the Russell 2000 and XSU
As the sun rises on January 1, 2026, the financial landscape is witnessing a profound shift that many analysts have anticipated for years: the definitive return of the U.S. small-cap sector. After a... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.